Skip to main content

Table 2 Predictive factors of overall mortality in the entire population of IPF patients treated with antifibrotics

From: Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment

  Univariate analysis Multivariate analysis
  HR (95% CI) p Value HR (95% CI) p Value
Sex Female – – – –
  Male 1.33 (0.51–3.49) 0.55 – –
Age at diagnosis (years)  < 70 – – – –
   ≥ 70 1.26 (0.61–2.58) 0.52 – –
BMI (kg/m2)  < 26 – – – –
 ≥ 26 0.85 (0.41–1.73) 0.66 – –
Smoking history (packyears)  < 10 – – – –
 ≥ 10 1.72 (0.83–3.59) 0.14 – –
Smoking status No – – – –
Current 1.91 (0.36–10.01) 0.44 – –
Former 1.93 (0.76–4.88) 0.16 – –
Gastroesophageal reflux No – – – –
Yes 0.26 (0.11–0.64) 0.003 0.11 (0.09–1.6) 0.1
Cardiovascular diseases No – – – –
Yes 1.57 (0.69–3.56) 0.27 – –
Metabolic syndrome No – – – –
Yes 0.90 (0.42–1.92) 0.79 – –
Treatment type Nintedanib –   – –
Pirfenidone 2.27 (0.78–6.60) 0.13 – –
MUC5B rs35705950 TT/TG – – – –
GG 2.39 (1.12–5.06) 0.02 1.75 (0.09–31.8) 0.7
Respiratory failure at rest (months)  ≥ 26 – – – –
 < 26 9.44 (4.10–21.77)  < 0.0001 36.7 (2.83–47.7) 0.006
Respiratory failure on effort (months)  ≥ 19 – – – –
 < 19 4.54 (2.06–10.00)  < 0.0001 4.96 (0.45–53.8) 0.18
Nausea and vomiting during treatment No – – – –
Yes 0.64 (0.24–1.68) 0.37 – –
Weight loss during treatment (Kg) No – – – –
Yes 0.96 (0.39–2.34) 0.93 – –
Diarrhea during treatment No – – – –
yes 0.17 (0.04–0.74) 0.02 0.45 (0.04–4.73) 0.5
Increase in AST and ALT No – – – –
  Yes 6.42 (0.78–52.41) 0.08 – –
FVC at treatment initiation (L)  ≥ 2.60 – – – –
 < 2.60 3.03 (1.42–6.48) 0.004 77.2 (2.99–199.0) 0.009
FVC at treatment initiation (%)  ≥ 77 – – – –
   < 77 1.80 (0.87–3.71) 0.11 – –
TLC at treatment initiation (%)  ≥ 73     
   < 73 1.89 (0.90–3.74) 0.09   
DLCO at treatment initiation (%)  ≥ 56 – – – –
 < 56 1.30 (0.64–2.65) 0.45 – –
FVC after 1-yr of antifibrotic drug (L)  ≥ 2.56 – – – –
 < 2.56 2.25 (1.08–4.94) 0.04 0.16 (0.01–2.21) 0.17
FVC decline in 1-yr of antifibrotic drug (ml)  < 50 – – – –
 ≥ 50) 1.13 (0.52–2.47) 0.74 – –
FVC after 1-yr of antifibrotic drug (%)  ≥ 78 – – – –
 < 78) 2.61 (1.10–6.19) 0.03 0.68 (0.10–4.23) 0.68
FVC decline in 1-yr of antifibrotic drug (%)  < 1.02 – – – –
 ≥ 1.02 1.44 (0.67–3.12) 0.34 – –
Disease progression Stables – – – –
Progressors 2.12 (0.90–4.98) 0.08 – –
TLC after 1-yr of antifibrotic drug (%)  ≥ 69 – – – –
 < 69 2.30 (1.04–5.08) 0.04 7.07 (0.95–52.66) 0.56
TLC decline in 1-yr of antifibrotic drug (%)  < 3.02 – – – –
 ≥ 3.02 1.96 (0.85–4.49) 0.11 – –
DLCO after 1-yr of antifibrotic drug (%)  ≥ 54 – – – –
 < 54 1.47 (0.67–3.21) 0.33 – –
DLCO decline in 1-yr of antifibrotic drug (%)  < 0 – – – –
 ≥ 0 1.52 (0.69–3.35) 0.3 – –
  1. FVC forced vital capacity, TLC  total lung capacity, DLCO  lung diffusion carbon oxide, RF  respiratory failure, AST  aspartate aminotransferase; ALT  alanine aminostransferase. Values are expressed as HR (95%CI). Univariate and multivariate Cox proportional hazard regression tests were used to determine the relationship of clinical, functional and radiological characteristics with progression. P-values < 0.05 were considered statistically significant (bold values)
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us